首页|新型冠状病毒多种Omicron亚变异株利用TMEM106B感染宿主细胞特性的研究

新型冠状病毒多种Omicron亚变异株利用TMEM106B感染宿主细胞特性的研究

扫码查看
目的 研究跨膜蛋白106B(transmembrane protein 106B,TMEM106B)支持新型冠状病毒(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)多种 Omicron 亚变异株感染侵入的特性。方法 构建 TMEM106B-knockout Flp-In T-Rex 293 细胞系(TMEM106BKO),利用假病毒感染系统以及GFP1-10和GFP11的双荧光互补系统的合胞体形成实验检测TMEM106B在SARS-CoV-2多种Omicron亚变异株刺突蛋白(spike protein,S)介导的侵入和细胞-细胞融合中发挥的作用。结果 SARS-CoV-2 多种 Omicron 亚变异株对 TMEM106B-knockout Flp-In T-Rex 293 细胞的侵入效率存在不同程度的降低,并且TMEM106B可促进SARS-CoV-2多种Omicron亚变异株S蛋白介导的细胞-细胞融合。结论 TMEM106B可作为受体分子支持SARS-CoV-2多种Omicron亚变异株的侵入和细胞-细胞融合,为治疗新型冠状病毒感染提供新的思路。
Characterization of infections by various SARS-CoV-2 Omicron subvariants mediated by TMEM106B receptor
Objective To investigate the role of transmembrane protein 106B(TMEM106B)in supporting the entry of multiple Omicron subvariants of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).Methods TMEM106B-knockout Flp-In T-Rex293 cell line(TMEM106BKO)was constructed.The pseudoviral infection systems and the syncytia formation assay based on dual fluorescent complementary system of GFP1-10 and GFP11 were established to detect the role of TMEM106B in spike protein-mediated entry and cell-cell fusion during the infections by different SARS-CoV-2 Omicron subvariants.Results The SARS-CoV-2 Omicron subvariants showed varying degrees of reduced efficiency in infecting TMEM106BKO,and TMEM106B can facilitate cell-cell fusion mediated by spike protein of various SARS-CoV-2 Omicron subvariants.Conclusions TMEM106B acted as a receptor to support the entry and cell-cell fusion of multiple Omicron subvariants of SARS-CoV-2.It could be a new idea for the treatment of SARS-CoV-2 infection.

Transmembrane protein 106BSevere acute respiratory syndrome coronavirus 2Omicron subvariantm

王媛媛、陈丹瑛、刘雨欣、宋焱君、孙慧、张媛媛、赵学森

展开 >

北京大学地坛医院教学医院 100015

首都医科大学附属北京地坛医院传染病研究所 100015

跨膜蛋白106B 新型冠状病毒 Omicron亚变异株

国家重点研发计划北京市自然科学基金

2023YFC0872400M23005

2024

国际病毒学杂志
中华医学会,北京市疾病预防控制中心

国际病毒学杂志

CSTPCD北大核心
影响因子:1.826
ISSN:1673-4092
年,卷(期):2024.31(4)